A recent study from Queen Mary University of London has demonstrated that zilebesiran, an investigational drug, can significantly enhance blood pressure control in patients who struggle with standard medications. In the global KARDIA-2 trial involving 663 adults with poorly managed hypertension, participants receiving a twice-yearly injection of zilebesiran alongside their existing treatments achieved greater reductions in blood pressure compared to those on standard therapy alone. This innovative approach targets the liver protein angiotensinogen, which is crucial for blood pressure regulation, allowing blood vessels to relax and thus lowering blood pressure effectively.

The implications of these findings are substantial, particularly in the context of hypertension, which affects approximately one in three adults in the UK and is a leading risk factor for cardiovascular events. Dr. Manish Saxena, a senior author of the study, emphasized that the long duration of zilebesiran’s effects could facilitate better management of hypertension for millions of patients, potentially reducing the burden of cardiovascular diseases that arise from uncontrolled blood pressure. The study’s results, published in JAMA, highlight the drug’s efficacy and safety when combined with first-line antihypertensive medications.

The introduction of a biannual injection for hypertension management could significantly alter current treatment paradigms and drug development timelines. By shifting the focus from daily oral medications to long-acting injectable therapies, researchers and clinicians may be able to improve patient adherence and outcomes in hypertension management. Future studies, including the upcoming KARDIA-3 trial, will further explore zilebesiran’s benefits in high-risk populations, potentially paving the way for a new standard in hypertension treatment.

Source: sciencedaily.com